Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin

R D Guttmann1, C Flemming

  • 1Centre for Clinical Immunobiology and Transplantation, McGill University, Montréal, Quebec, Canada.

Clinical Transplantation
|June 1, 1997
PubMed
Summary

Rabbit anti-human thymocyte IgG (Thymoglobuline) is well-tolerated in renal transplant patients. This immunosuppression protocol shows good short- and long-term outcomes, with low rates of recurrent rejection and manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards a more accurate quantitative assessment of seasonal Cryptosporidium infection risks in surface waters using species and genotype information.

Water research·2016
Same author

Cellular immune abnormalities and autoreactive T lymphocytes in insulin-dependent diabetes mellitus in rats.

Immunology today·2014
Same author

Fate of Clostridium difficile during wastewater treatment and incidence in Southern Ontario watersheds.

Journal of applied microbiology·2014
Same author

Increased risk for Campylobacter jejuni and C. coli infection of pet origin in dog owners and evidence for genetic association between strains causing infection in humans and their pets.

Epidemiology and infection·2013
Same author

Colles's Fracture.

Postgraduate medical journal·2011
Same author

A Case of Old Hip Disease.

Postgraduate medical journal·2011

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation Medicine

Background:

  • Renal transplantation is a critical treatment for end-stage renal disease.
  • Optimizing immunosuppression protocols is essential for improving graft survival and patient outcomes.
  • Rabbit anti-human thymocyte IgG (Thymoglobuline) is a potential induction agent in renal transplantation.

Purpose of the Study:

  • To evaluate the efficacy and safety of a quadruple sequential immunosuppression protocol using Thymoglobuline in renal allograft recipients.
  • To assess the impact of Thymoglobuline on acute rejection rates, graft survival, and patient survival.
  • To characterize the side-effect profile of Thymoglobuline in this patient cohort.

Main Methods:

  • Retrospective analysis of 108 consecutive renal transplant patients receiving 109 allografts.

Related Experiment Videos

  • Utilized a quadruple sequential immunosuppression regimen including Thymoglobuline, azathioprine, tapering corticosteroids, and delayed cyclosporine A.
  • Monitored serum creatinine, patient survival, allograft survival, and adverse events.

    • Main Results:

    • The quadruple regimen demonstrated favorable 4-year patient survival (96.6%) and allograft survival (83.6%).
    • The incidence of acute rejection was 32%, with Thymoglobuline retreatment showing a low rate of recurrent rejection.
    • Thymoglobuline was generally well-tolerated, with common side effects including fever, chills, and leucopenia, and a low incidence of other adverse events.

    Conclusions:

    • Thymoglobuline, as part of a quadruple sequential immunosuppressive regimen, is well-tolerated in renal transplantation.
    • This protocol is associated with good short- and long-term outcomes, including favorable graft and patient survival rates.
    • Thymoglobuline appears effective in preventing recurrent acute rejection episodes.